Skip to content

Study · Randomized controlled trial · n = 124 · 2003

5 results

Improvement in adult height after growth hormone treatment in adolescents with short stature born small for gestational age: results of a randomized controlled study.

Carel JC, Chatelain P, Rochiccioli P, Chaussain JL

The Journal of clinical endocrinology and metabolism1 Apr 2003Cited by 82 (Europe PMC)

PMID12679443 (opens in a new tab)DOI10.1210/jc.2002-021123 (opens in a new tab)PepBankPUB-12679443
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In short adolescents born SGA, adult height was -2.1 +/- 1.0 SDS with GH versus -2.7 +/- 0.9 without treatment (P < 0.005), a 0.6 SDS difference (95% CI 0.2-0.9).

    In plain wordsIn short adolescents born SGA, growth hormone increased adult height versus no treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseAdult height
    Study

    n = 124

    Comparator
    no treatment
    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    0.067 mg/kg.d · 2.7 +/- 0.6 yrAs given in this study (human).

    Measurements

    Adult height SDS
    −2.7 SDS
    control group, +/- 0.9 as written
    Adult height SDS
    −2.1 SDS
    GH-treated group, +/- 1.0 as written
    Difference in adult height SDS
    0.6 SDS
    treated versus control, 95% CI 0.2-0.9
    P value
    < 0.005 P value
    adult height, treated versus control

    Source sentences

    Summary
    AH was -2.7 +/- 0.9 and -2.1 +/- 1.0 SDS in the control and treated groups, respectively (P < 0.005).
    4 context sentences
    Summary · context
    The groups differed by 0.6 SDS units (95% confidence interval, 0.2-0.9).
    Summary · context
    A total of 168 short children born SGA (age, 10.5 yr for girls and 12.5 yr for boys) were randomly assigned to receive either 0.067 mg/kg.d GH until attainment of AH or no treatment.
    Summary · context
    In this per-protocol analysis, 91 of 102 patients in the treated group and 33 of 47 patients in the control group were followed to AH.
    Summary · context
    Treatment duration was 2.7 +/- 0.6 yr.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In short adolescents born SGA, height gain was 1.1 +/- 0.9 SDS with GH versus 0.5 +/- 0.8 SDS without treatment (P = 0.002).

    In plain wordsIn short adolescents born SGA, growth hormone increased height gain versus no treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeight gain
    Study

    n = 124

    Comparator
    no treatment
    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    0.067 mg/kg.d · 2.7 +/- 0.6 yrAs given in this study (human).

    Measurements

    Height gain SDS
    0.5 SDS
    control group, +/- 0.8 as written
    Height gain SDS
    1.1 SDS
    GH-treated group, +/- 0.9 as written
    P value
    0.002 P value
    height gain, treated versus control

    Source sentences

    Summary
    Height gain was 0.5 +/- 0.8 and 1.1 +/- 0.9 SDS in the control and treated groups, respectively (P = 0.002).
    3 context sentences
    Summary · context
    A total of 168 short children born SGA (age, 10.5 yr for girls and 12.5 yr for boys) were randomly assigned to receive either 0.067 mg/kg.d GH until attainment of AH or no treatment.
    Summary · context
    In this per-protocol analysis, 91 of 102 patients in the treated group and 33 of 47 patients in the control group were followed to AH.
    Summary · context
    Treatment duration was 2.7 +/- 0.6 yr.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In short adolescents born SGA, multivariate analysis confirmed an independent GH treatment effect of 0.6 SDS.

    In plain wordsIn short adolescents born SGA, adjusted analysis confirmed a growth hormone benefit on height.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseAdjusted treatment effect
    Study

    n = 124

    Comparator
    no treatment
    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    0.067 mg/kg.d · 2.7 +/- 0.6 yrAs given in this study (human).

    Measurements

    Independent effect of GH treatment (multivariate analysis)
    0.6 SDS
    versus no treatment
    Independent effect of treatment duration (multivariate analysis)
    0.4 SDS/yr
    per year of treatment

    Source sentences

    Summary
    Multivariate analyses confirmed the independent effects of treatment (0.6 SDS) and treatment duration (0.4 SDS/yr).
    3 context sentences
    Summary · context
    A total of 168 short children born SGA (age, 10.5 yr for girls and 12.5 yr for boys) were randomly assigned to receive either 0.067 mg/kg.d GH until attainment of AH or no treatment.
    Summary · context
    In this per-protocol analysis, 91 of 102 patients in the treated group and 33 of 47 patients in the control group were followed to AH.
    Summary · context
    Treatment duration was 2.7 +/- 0.6 yr.
  4. 04HumanNon-randomized trialSafety outcome

    In short adolescents born SGA, GH treatment tolerance was excellent.

    In plain wordsIn short adolescents born SGA, growth hormone treatment tolerance was excellent.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableTreatment tolerance
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.067 mg/kg.d · 2.7 +/- 0.6 yrAs given in this study (human).

    Source sentences

    Summary
    Treatment tolerance was excellent.
    3 context sentences
    Summary · context
    A total of 168 short children born SGA (age, 10.5 yr for girls and 12.5 yr for boys) were randomly assigned to receive either 0.067 mg/kg.d GH until attainment of AH or no treatment.
    Summary · context
    In this per-protocol analysis, 91 of 102 patients in the treated group and 33 of 47 patients in the control group were followed to AH.
    Summary · context
    Treatment duration was 2.7 +/- 0.6 yr.
  5. 05HumanObservational studyOther

    In short adolescents born SGA, multivariate analysis found a treatment duration effect of 0.4 SDS/yr.

    In plain wordsIn short adolescents born SGA, longer growth hormone treatment was linked to greater height benefit.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseTreatment duration effect
    Study

    n: not reported in source

    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    0.067 mg/kg.d · 2.7 +/- 0.6 yrAs given in this study (human).

    Measurements

    treatment duration effect on adult height
    0.4 SDS/yr
    multivariate analysis, short adolescents born SGA

    Source sentences

    Summary
    Multivariate analyses confirmed the independent effects of treatment (0.6 SDS) and treatment duration (0.4 SDS/yr).
    3 context sentences
    Summary · context
    A total of 168 short children born SGA (age, 10.5 yr for girls and 12.5 yr for boys) were randomly assigned to receive either 0.067 mg/kg.d GH until attainment of AH or no treatment.
    Summary · context
    In this per-protocol analysis, 91 of 102 patients in the treated group and 33 of 47 patients in the control group were followed to AH.
    Summary · context
    Treatment duration was 2.7 +/- 0.6 yr.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.